Anthony Rothschild, MD, a professor at the Irving S. and Betty Brudnick Endowed Chair of Psychiatry, University of Massachusetts Medical School, says that many primary care physicians feel more comfortable prescribing newer anti-depressant drugs with fewer side effects.
Anthony Rothschild, MD, a professor at the Irving S. and Betty Brudnick Endowed Chair of Psychiatry, University of Massachusetts Medical School, says that many primary care physicians feel more comfortable prescribing newer anti-depressant drugs with fewer side effects.
He adds that patients who are diagnosed with depression for the 1st time are often done so by their primary care physician. This is because he or she may not have believed they were suffering from depression and would not have previously considered contacting a psychiatrist. Physicians are in a “unique position” to diagnose patients with depression and to prescribe an anti-depressant drug regimen.
However, Dr Rothschild explains that there are certain types of depression that should not be handled by primary care physicians alone. He recommends that primary care physicians refer patients who suffer from conditions such as psychotic depression or bipolar disorder to a psychiatrist, as they can be more complicated.
“It’s not unusual for me to see patients with depression who may have had 1 trial of an anti-depressant from their primary care physician,” Dr Rothschild says. “If it works out, I don’t ever see them. But, if it doesn’t work out then and it becomes a little more complicated, then the primary care doctor will refer the patient to a psychiatrist.”
Dr Rothschild also serves as director at the UMass Medical Depression Center and Center for Psychopharmacologic Research and Treatment, and as a program director at the Mood Disorders Comprehensive Consultation Clinic at UMass Memorial Medical Center.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More